Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer
NCT ID: NCT01114464
Last Updated: 2016-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
250 participants
OBSERVATIONAL
2010-01-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ovarian Reserve in Premenopausal Breast Cancer
NCT01726322
Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients
NCT02430103
Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer
NCT03731845
Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility
NCT01614704
Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer
NCT03795246
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
young women with breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* suffering from breast cancer
* treated with adjuvant or neoadjuvant chemotherapy
18 Years
39 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Barrière, MD
Role: PRINCIPAL_INVESTIGATOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Bergonié
Bordeaux, , France
Centre François BACLESSE
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
CRLC de Bourgogne Georges François Leclerc
Dijon, , France
Centre Oscar Lambret
Lille, , France
Centre de Lutte Contre le Cancer Léon Bérard
Lyon, , France
Centre Val d'Aurelle - Paul Lamarque
Montpellier, , France
Institut Curie
Paris, , France
Institut Jean Godinot
Reims, , France
Centre Eugène Marquis
Rennes, , France
Centre de Lutte Contre le Cancer Nantes Atlantique René Gauducheau
Saint-Herblain, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Loubersac S, Chaillot M, Reignier A, Lefebvre T, Dezellus A, Colombel A, Barriere P, Masson D, Freour T. Serum androgen dynamics in young women aged 18-40 treated with chemotherapy for breast cancer: an observational, multicentric, prospective study in France. Hum Fertil (Camb). 2024 Dec;27(1):2350758. doi: 10.1080/14647273.2024.2350758. Epub 2024 Jul 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRD/09/06-J
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.